Private Companies
Delix Therapeutics to start clinical trial on novel psychoplastogen drug
DLX-001 is a non-hallucinogenic compound intended to treat various mental health conditions
The post Delix Therapeutics to start clinical trial on novel…
Delix Therapeutics, a neuroscience company based in Boston Massachusetts, has received approval for a Phase I clinical trial examining its novel non-hallucinogenic psychoplastogen drug DLX-001.
The company announced the regulatory approval for the study on Tuesday and plans to enroll 100 healthy volunteers in the trial at the Center for Human Drug Research in the Netherlands. The company has not specified when the trial will begin.
DLX-001 is the first approved psychoplastogen from Delix’s platform, based on the work of the company’s co-founder David E. Olson.
His research at the University of California, Davis, led to the discovery of novel psychoplastogens with significant therapeutic potential in preclinical models, without the hallucinogenic side effects of earlier generations.
UC Davis established an Institute for Psychedelics and Neurotherapeutics in February with the intention of advancing safe and effective treatments for diseases such as depression, Parkinson’s, PTSD, substance use disorders and Alzheimer’s.
Read more: Delix gets recognized as leading start-up by Nature Biotechnology
Read more: PhD graduates from UBC launch new company in Nevada
DLX-001 is a compound from Delix’s extensive library of active compounds that are said to promote enduring neuroplasticity, with efficacy comparable to or better than natural psychedelic compounds. Unlike the natural compounds, DLX-001 is not psychoactive, even at high doses, which Delix says is evidenced by preclinical models.
“With the continued rise of mental health diagnoses across the globe and a significant lack of innovative treatment options available for those suffering, we are excited about the potential of psychoplastogens — especially scaleable non-hallucinogenic compounds — to treat a variety of conditions as safe and effective take-at-home medicines,” said Delix’s CEO Mark Rus, adding that this first in-human trial is the result of years of preclinical studies and results.
Delix was recognized as a leading start-up company in September last year by the renowned scientific journal Nature Biotechnology.
The company has established a substantial private investor base comprised of firms such as RA Capital, Artis Ventures and Dolby Family Ventures.
rowan@mugglehead.com
The post Delix Therapeutics to start clinical trial on novel psychoplastogen drug appeared first on Mugglehead Magazine.
psychoactive psychedelics psychedelic capital delix therapeutics delix research-
Law & Regulation1 week ago
Relmada loses another $21.8M, makes progress with clinical trials
-
Psychedelics6 days ago
BetterLife Obtains Excellent Animal Cardiopulmonary Safety Data for Oral BETR-001
-
Psychedelics5 days ago
atai Life Sciences Reports First Quarter 2024 Financial Results and Corporate Updates
-
Law & Regulation1 week ago
AbbVie, Gilgamesh Pharmaceuticals enter psychiatric drug deal
-
Psychedelics6 days ago
Optimi Health Receives Certificate of Analysis For MDMA 40mg and 60mg GMP Capsules
-
Law & Regulation5 days ago
FDA nod fuels Filament’s psychedelics push, but cash running short
-
Psychedelics6 days ago
Silo Pharma to Participate in FDA Meeting Exploring Emerging Therapeutic Interest in Ketamine
-
Psychedelics6 days ago
Cybin to Participate in the Alliance Global Partners Healthcare Company Showcase